bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Drop in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 271,400 shares, a decrease of 39.4% from the October 15th total of 447,500 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average daily volume of 115,100 shares, the short-interest ratio is currently 2.4 days.

Analyst Ratings Changes

Separately, Maxim Group initiated coverage on bioAffinity Technologies in a report on Tuesday, July 23rd. They issued a “buy” rating and a $6.00 target price on the stock.

bioAffinity Technologies Stock Down 1.5 %

Shares of NASDAQ BIAF traded down $0.02 during trading hours on Friday, hitting $1.31. The stock had a trading volume of 40,610 shares, compared to its average volume of 139,858. The company has a market capitalization of $17.59 million, a P/E ratio of -1.45 and a beta of 3.10. The firm’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $1.96. bioAffinity Technologies has a 52 week low of $1.21 and a 52 week high of $3.62. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.14 and a current ratio of 1.15.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.19) earnings per share for the quarter. bioAffinity Technologies had a negative net margin of 120.76% and a negative return on equity of 172.06%. The business had revenue of $2.40 million during the quarter.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC acquired a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.